Myungmoon teams up with Protherics over ReGel

Myungmoon Pharm said on September 24 that it signed a licensing agreement with London-based Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, to develop anti-inflammatory products using Protherics' novel proprietary local, sustained release drug delivery system ReGel (trademark).

Under the agreement, Myungmoon will pay a small upfront payment on...